Neurocrine Biosciences Inc. (NBIX) — RQD Stock Rating Cockpit
Neurocrine Biosciences Inc. (NBIX) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
Real cash coming in backs up reported profits (96% profit margin and healthy balance-sheet cushion).
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bullish on NBIX
15.7% ROIC with 96.0% gross margin and 5.03% FCF yield.
Altman-Z 8.13 and Piotroski 9/9 pass balance-sheet audit.
Put/Call 0.76x with 22/40 institutional & insider flow.
- ✓Strong cash generator (96% profit margin)—profits are backed by real money, not accounting tricks.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live NBIX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
NBIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +21.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NBIX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NBIX. Explore sector supply chains on /butterfly.
NBIX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell NBIX stock right now?
Neurocrine Biosciences Inc. (NBIX) currently earns a Roarable Rating of B (Buy — BUY) with 73/100 RQD Confidence. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support.
What is NBIX's 12-month price target and RQD AI Jury consensus?
NBIX's 12-month base price target is $156.26 (range $120.03 to $195.43), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.